Beacon Therapeutics recently announced a successful funding round, raising an impressive $170,000,000. This ophthalmic gene therapy company, established in 2023, specializes in restoring and enhancing the vision of patients battling various prevalent and rare retinal diseases that can lead to blindness. With a robust scientific background, the company boasts a late-stage development candidate for X-linked retinitis pigmentosa (XLRP) and two promising preclinical programs targeting dry age-related macular degeneration (AMD) and cone-rod dystrophy (CRD). Beacon's lead development candidate, AGTC-501, is currently in Phase II clinical trials for treating XLRP, a condition predominantly affecting young men due to mutations in the RPGR gene. This gene therapy approach aims to express the full-length RPGR protein to counteract the photoreceptor damage caused by XLRP. With funding from Syncona and other investors like Oxford Science Enterprises, Beacon Therapeutics is well-positioned to advance its cutting-edge research and potentially transform the lives of patients suffering from retinal diseases. Visit www.beacontx.com to learn more about the company and its groundbreaking work in the field of ophthalmic gene therapy.
Beacon Therapeutics Secures $170 Million in Series B Funding for Groundbreaking Ophthalmic Gene Therapy Innovations
Recently funded 路 $170.0M Series bHealthcare
Get the full Beacon Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | NEW ID | Series b | $705.2K | today |
| 2 |  Arist United States | Series b | $14.1M | today |
| 3 |
